Ayala Pharmaceuticals Inc ADXS

SA ARTICLE: ADXS 12% DOWN DESPITE ADXS-503 SHOWING + RESULTS

[Humanist]

Advaxis down 12% despite ADXS-503 shows sustained tumor control in mid-stage lung cancer trial
Oct. 26, 2020 8:46 AM ET|About: Advaxis, Inc. (ADXS)|By: Mamta Mayani, SA News Editor 

Advaxis (NASDAQ:ADXS) announces updated clinical results from the combination arm of its Phase 1/2 study evaluating ADXS-503 in combination with Merck's (NYSE:MRK) KEYTRUDA (pembrolizumab), an anti-PD-1 therapy in non-small cell lung cancer (NSCLC).

ADXS-503 is the first drug construct from the Company’s ADXS-HOT off-the-shelf, cancer-type specific, immunotherapy program.
Key data updates for the first 6 evaluable patients include:

Disease control rate of 67% (4/6 patients) and overall response rate of 17% (1/6 patients) achieved after immediate prior progression on KEYTRUDA.

Sustained and durable clinical benefit with the first two treated patients remaining on treatment for over 43 and 33 weeks.
Approximate 50% improvement observed in disease control rate versus the rates reported in other checkpoint rechallenge studies.

Stable disease (SD) confirmed on 13 week-scan in a patient with squamous NSCLC who received Pembrolizumab for ~15 months and SD on 6 week-scan in non-squamous NSCLC patient who receiving Pembrolizumab for ~14 months, including combination therapy with chemotherapy.
Shares are down 12% premarket.